Vivimed Labs Key Ratios
NSE: VIVIMEDLAB | BSE: 532660
₹7.07
As on 28-Aug-2026 13:11IST
Market cap
₹59 Cr
Revenue (TTM)
₹70 Cr
P/E Ratio
--
P/B Ratio
-0.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -24.95 | -53.15 | -39.80 | -27.95 | -39.47 |
| EBIT | -876.12 | -1,805.90 | -436.45 | 11.77 | -229.40 |
| Net Profit | -788.75 | -2,527.21 | -452.15 | 13.52 | -176.87 |
| EPS | -788.75 | -2,527.15 | -452.15 | 13.52 | -176.87 |
| Book Value | -- | -- | -68.36 | -160.75 | -168.90 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-25 | Mar-24 |
| EBIT-Margin
| -78.80 | -47.13 | -255.02 | -28.59 | -35.43 |
| Net Margin
| -81.60 | -53.27 | -231.21 | -26.49 | -28.57 |
| Return on equity
| -91.87 | -47.18 | -- | 0.00 | 0.00 |
| Return on Capital
| -21.19 | -16.20 | -- | -9.07 | -12.01 |
| Return on Assets
| -15.30 | -9.31 | -21.08 | -3.42 | -4.67 |
| Debt to Equity (x)
| -- | -- | -0.34 | -5.14 | -8.67 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
-9.07
|
-12.01
|
-55.28
|
-3.54
|
|
Peer Median
|
--
|
14.72
|
18.85
|
11.60
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
--
|
--
|
-200.51
|
-18.80
|
|
Peer Median
|
10.86
|
11.67
|
14.92
|
11.46
|
--
|
ROA
-21.08
Lower than Peers by 27.82
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-21.08
|
-3.42
|
-4.67
|
-29.06
|
-5.29
|
|
Peer Median
|
6.74
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
-255.02
Lower than Peers by 267.72
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-255.02
|
-28.59
|
-35.43
|
-157.88
|
-11.00
|
|
Peer Median
|
12.69
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
-231.21
Lower than Peers by 240.07
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-231.21
|
-26.49
|
-28.57
|
-174.69
|
-28.36
|
|
Peer Median
|
8.86
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
0.00
|
-10.09
|
-17.11
|
-117.65
|
-20.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-39.80
Lower than Peers by 47.94
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-39.80
|
-22.00
|
-20.33
|
-21.15
|
-72.46
|
|
Peer Median
|
8.14
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
-436.45
Lower than Peers by 453.70
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-436.45
|
37.07
|
82.12
|
-1,031.34
|
-10.56
|
|
Peer Median
|
17.24
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
-452.15
Lower than Peers by 469.00
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-452.15
|
29.67
|
86.17
|
-385.64
|
5.89
|
|
Peer Median
|
16.85
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
-452.15
Lower than Peers by 462.75
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-452.15
|
29.67
|
86.17
|
-385.64
|
5.89
|
|
Peer Median
|
10.60
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
-68.36
|
-3,156.33
|
-99.56
|
-17.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.34
Lower than Peers by 0.38
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-0.34
|
-5.14
|
-8.67
|
266.22
|
1.10
|
|
Peer Median
|
0.04
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
-8.89
|
-57.38
|
5.70
|
0.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.37
Lower than Peers by 1.35
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
0.37
|
0.80
|
0.84
|
0.80
|
1.36
|
|
Peer Median
|
1.72
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
0.35
Lower than Peers by 0.83
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
0.35
|
0.66
|
0.68
|
0.61
|
0.71
|
|
Peer Median
|
1.17
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
-41.16
Lower than Peers by 49.03
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-41.16
|
-9.69
|
-14.36
|
-8.13
|
-0.62
|
|
Peer Median
|
7.86
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
64.77
Higher than Peers by 38.99
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
64.77
|
63.74
|
55.56
|
39.63
|
36.82
|
|
Peer Median
|
25.79
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
0.08
Lower than Peers by 0.58
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
0.08
|
0.12
|
0.15
|
0.17
|
0.19
|
|
Peer Median
|
0.67
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
246.32
|
192.18
|
157.55
|
149.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
192.78
|
176.07
|
312.65
|
381.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
254.58
|
253.55
|
65.28
|
90.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
184.52
|
114.70
|
404.91
|
441.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-0.33
Lower than Peers by 40.08
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-0.33
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.76
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
-0.23
Lower than Peers by 4.45
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-0.23
|
--
|
--
|
38.89
|
0.37
|
|
Peer Median
|
4.21
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
-3.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
-3.11
|
-45.38
|
-17.10
|
-2.31
|
-71.91
|
|
Peer Median
|
--
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
59
Lower than Peers by 7,325
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vivimed Labs
|
59
|
--
|
--
|
55
|
120
|
|
Peer Median
|
7,384
|
4,851
|
2,099
|
15,272
|
--
|